HandiHaler

DEVICE8 trials

Sponsors

Boehringer Ingelheim, GlaxoSmithKline, University of Crete

Conditions

Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic Obstructive

Phase 2

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT02175342

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 1998-03-01Updated: 2025-01-31

Phase 3

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD

CompletedNCT00239447

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2002-11-26End: 2004-04-29Target: 131Updated: 2023-12-01

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00281567

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2002-08-31Updated: 2013-11-01

Phase 4

Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices

CompletedNCT02184624

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2014-08-28End: 2015-07-31Updated: 2017-05-23

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT03474081

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2018-03-29End: 2019-07-17Updated: 2021-07-15

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT03478696

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2018-06-25End: 2019-03-18Updated: 2020-10-28

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT03478683

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2018-06-25End: 2019-03-14Updated: 2020-10-28

Unknown Phase

Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients

CompletedNCT02331940

University of CreteChronic Obstructive Pulmonary Disease

Start: 2010-03-31End: 2014-09-30Updated: 2017-03-30

Related Papers

Peak Inspiratory Flow Rate in COPD: An Analysis of Clinical Trial and Real-World Data.

2021-04-1215 citations

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.

2020-05-2930 citations